CCM
STRO icon

CAAS Capital Management’s Sutro Biopharma STRO Stock Holding History

CAAS Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,598
Closed -$937K – 898
2022
Q4 		$937K Buy
+11,598
New +$806K 0.06% 288

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

CAAS Capital Management's STRO Position: Q1 2023 in Review

CAAS Capital Management sold out of Sutro Biopharma (STRO) in Q1 2023, closing a stake of 11,598 shares — an estimated $937K sold.

CAAS Capital Management first reported a position in STRO in Q4 2022 and held it in 1 quarter. The position peaked at $937K in Q4 2022. 115 funds tracked by Wall St. Rank hold STRO as of Q1 2023.

  • CAAS Capital Management reported no remaining Sutro Biopharma position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 11,598 Sutro Biopharma shares in Q1 2023, an estimated $937K.
  • CAAS Capital Management first reported a position in Sutro Biopharma in Q4 2022 and held it in 1 quarter.
  • CAAS Capital Management's Sutro Biopharma position peaked at $937K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.